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OBJECTIVES The purpose of this study was to compare the effect of changes in flow rate on the mitral valve
area (MVA) derived from two-dimensional echocardiographic planimetry and Doppler
pressure half-time (PHT) methods in patients with mitral stenosis (MS).
BACKGROUND Dobutamine stress echocardiography has been proposed as a means of assessing the severity
of MS. However, data regarding the effect of an increase in flow rate on MVA are limited.
If MVA is indeed flow-dependent, this has important implications for the assessment of the
severity of MS, particularly in the setting of reduced cardiac output (CO).
METHODS Dobutamine echocardiography was performed in 57 patients with isolated MS who were in
sinus rhythm. The MVA was determined by planimetry and Doppler PHT methods.
RESULTS Cardiac output increased by 50% in 27 patients (group I) and by 50% in 30 patients
(group II). In group I, the MVA by planimetry increased by only 10.6  2% and the MVA
by PHT increased by 21.9  4.8%. These changes were similar to those observed in group
II (10.7  3% and 14.8  4%, respectively; p  NS), despite a much smaller increase in CO.
A clinically important change (from the severe to mild category) occurred in only one patient
when using the PHT method and in none by planimetry.
CONCLUSIONS Changes in flow rate result in small but clinically insignificant changes in echocardiographic
MVA measurement. These methods provide an accurate assessment of MS severity in a
majority of patients, independent of changes in flow rate. (J Am Coll Cardiol 2002;40:
1809–15) © 2002 by the American College of Cardiology Foundation
The severity of mitral stenosis (MS) is assessed by measur-
ing transmitral pressure gradients and/or the stenotic mitral
valve area (MVA) at the orifice (1). The MVA is one of the
major indexes used to categorize severity, guide therapy, and
monitor the progression of disease (2). Valve area measure-
ment methods in MS were developed in an attempt to
provide a flow-independent assessment of mitral valve
stenosis. Historically, this value has been derived from the
Gorlin formula, and more recently, by echocardiography.
Two-dimensional echocardiographic planimetry (3) and
Doppler pressure half-time (PHT) methods yield an ana-
tomic valve area (4). These two methods correlate well with
each other and are commonly used techniques for assessing
MVA. Hemodynamic studies have suggested that MVA is
not constant, but varies with changes in flow (5–8). The
significance of these flow-related changes in MVA remains
unclear. Flow dependence may occur due to true widening
of the orifice with increased flow or due to the flow-rate
dependence of the formula. It has been suggested that
MVA derived by PHT (PHT-MVA) is flow-dependent
(5,6). However, no systematic studies are available in a large
number of patients with varying degrees of MS severity, and
little is known about the effect of a flow increase on true
anatomic MVA. Although PHT is known to be dependent
on the heart rate (HR), clinical studies examining the effect
of increasing flow volume on Doppler PHT-MVA have not
studied the independent effects of an increase in volume
versus an increase in HR.
Thus, the data presently available do not clearly prove
whether the degree of MS varies with changes in the
valve-opening force. Because the determinants of this force
are transvalvular flow, transmitral gradient, and flow veloc-
ity, the assessment of MS by Doppler or planimetry meth-
ods might be altered in low-output states. The purposes of
this investigation were to: 1) determine whether anatomic
MVA measured by planimetry and MVA derived by PHT
change with flow rate; 2) examine the differential effects of
an increase in flow on MVA determined by the two
methods; and 3) determine whether the flow-related
changes in MVA are clinically significant, so as to alter the
classification of severity used in clinical decision-making.
METHODS
Study patients. The study protocol was approved by the
institutional Research and Ethics Committee. Written,
informed consent was obtained from each patient or his or
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her guardian. The study included 59 consecutive patients
with isolated rheumatic MS who were in sinus rhythm. Two
patients were subsequently excluded because of the devel-
opment of significant ventricular arrhythmia during the
dobutamine infusion. The remaining 57 patients who com-
pleted the study protocol included 17 males and 40 females
(age range 14 to 55 years; mean 29 years). Patients with
atrial fibrillation, New York Heart Association functional
class IV symptoms, moderate or severe mitral or aortic
regurgitation, poor acoustic windows, sinus tachycardia,
previous balloon or operative mitral commissurotomy, sig-
nificant mitral valve calcification, or any systemic illness
were excluded.
Transthoracic echocardiography. A transthoracic annular-
array, dual-frequency transducer (3.25/2.5 MHz) interfaced
to a commercially available ultrasound unit (CFM 800
VingMed, VingMed Sound A/S, Horten, Norway) was
used to obtain echocardiographic images. The electrocar-
diogram was obtained simultaneously, and the HR was
calculated from the RR intervals. The entire examination
was recorded on 0.5-in. VHS videotape. Patients were
examined in the left lateral decubitus position after resting
for 30 min and then during dobutamine infusion. For the
assessment of intraobserver variability, baseline imaging was
repeated after 24 h in 10 patients. The patients underwent
a complete echocardiographic examination, including trans-
thoracic imaging, pulsed-wave Doppler, continuous-wave
Doppler, and color flow mapping. Two-dimensional echo-
cardiographic measurements included the left ventricular
outflow tract (LVOT) diameter, planimetry of the mitral
valve orifice in the parasternal short-axis view, and mitral
valve score. Pulsed-wave Doppler interrogation of the
LVOT was performed to obtain the LVOT velocity-time
integral (stroke distance), and continuous-wave Doppler
examination of the mitral valve orifice in the apical four-
chamber view were recorded to obtain: 1) the diastolic filling
period; 2) the peak and mean transmitral pressure gradients;
and 3) the transmitral velocity-time integral. The MVA
measured by two-dimensional echocardiography (2DE-
MVA) was determined off-line at baseline and at steady-
state dobutamine infusion. All measurements were obtained
by planimetry of the mitral valve orifice area in the paraster-
nal short-axis view at the valve tips by an experienced
observer (3). Measurements of MVA were consistently
made at the same location, using optimal gain settings. The
PHT-MVA was determined using the continuous-wave
Doppler spectrum of transmitral flow (4). Cardiac output
(CO) was calculated as: (LVOT velocity-time integral) 
0.785  (LVOT diameter)2  (HR) (9). At least five
consecutive measurements of MVA were averaged for a
given hemodynamic profile. The mitral valve morphologic
score was assessed in all patients (10). Based on planimetry,
severe MS was defined as MVA 1 cm2; moderate MS as
MVA 1.1 to 1.4 cm2; and mild MS as MVA 1.5 cm2.
Hemodynamic manipulation. Changes in CO were in-
duced by an infusion of dobutamine. After obtaining base-
line echocardiographic and Doppler hemodynamic data, a
graded infusion of dobutamine was begun at 5 g/kg body
weight/min and doubled every 5 min until an increase in
CO of 50% or an infusion rate of 20 g/kg/min was
obtained. Repeat echocardiographic and Doppler hemody-
namic data were recorded during steady-state dobutamine
infusion. Heart rate and sphygmomanometric blood pres-
sure were recorded every 2 min.
Analysis of data. The MVA values obtained by two-
dimensional echocardiography and PHT methods were
compared at baseline and at a peak dose of dobutamine
infusion, with regard to absolute values, percent differences,
and categories of MS severity. The absolute difference in
MVA, percent change in HR, and percent change in CO
were calculated for all patients. Patients were classified into
two groups based on the degree of increase in CO after
dobutamine infusion: patients in group I had an increase of
50% in CO from baseline, and group II patients had a CO
increase of 50%.
Statistical analysis. Results are presented as the mean
value  SEM. Within each group, data at baseline and at
maximal flow conditions were compared using the paired
Student t test. The percent change from baseline to peak
dobutamine infusion was compared between the two groups
by using the unpaired t test. Differences were considered
significant at p  0.05. Interobserver and intraobserver
variabilities are expressed as the mean difference SD. The
Karl-Pearson coefficient of correlation was used to deter-
mine the relationship between changes in MVA and other
hemodynamic variables.
RESULTS
Based on two-dimensional echocardiographic planimetry,
22 patients had severe MS (MVA 1.0 cm2) and 35 had
mild to moderate MS (MVA 1.0 cm2) at baseline. No
patients had regional wall motion abnormalities. The base-
line characteristics of the study population are shown in
Table 1. The mean peak dobutamine dose was 20  3
g/kg per min in group I and 16.5  2 g/kg per min in
group II. Hemodynamic measurements and MVAs at
baseline and during dobutamine infusion are shown in
Table 2. In group I, the mean mitral gradient increased
Abbreviations and Acronyms
CO  cardiac output
HR  heart rate
LVOT  left ventricular outflow tract
MS  mitral stenosis
MVA  mitral valve area
PHT  pressure half-time
PHT-MVA  mitral valve area measured by pressure
half-time
2DE-MVA  mitral valve area measured by two-
dimensional echocardiography
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from 9  2 mm Hg at baseline to 16  4 mm Hg during
dobutamine (p  0.0001); in group II, the mean gradient
increased from 10  2 mm Hg to 16  3 mm Hg,
respectively (p  0.0001). Changes in CO during dobut-
amine administration are shown in Figure 1. The mean HR
increased from 77  3 beats/min at baseline to 117  4
beats/min during dobutamine in group I (p  0.0001), and
increased from 83  3 beats/min (at baseline) to 109  4
beats/min during dobutamine in group II (p  0.0001).
Twenty-four patients had a mitral valve score 6 (mean
8.13 0.25); these patients demonstrated a small change in
2DE-MVA (1.17  0.07 cm2 to 1.31  0.08 cm2, p 
0.0002) and in PHT-MVA (1.14  0.07 cm2 to 1.43 
0.09 cm2, p  0.00002). These changes were similar in
magnitude to those of patients (n  33) with a mitral valve
score 6 (mean 5.93  0.07): 2DE-MVA increased from
1.24  0.06 cm2 to 1.37  0.07 cm2 (p  0.0017);
PHT-MVA increased from 1.24 0.06 cm2 to 1.43 0.08
cm2 (p  0.0041). Changes in MVA for patients in groups
I and II are demonstrated in Figures 2 and 3, respectively,
and in Tables 3 and 4. Differences in changes in MVA and
hemodynamic variables are shown in Table 5. Changes in
2DE-MVA (10.7  2% vs. 10.7  3%, p  0.994) and
PHT-MVA (21.9  4.8% vs. 14.8  4%, p  0.25) were
similar in the two groups, despite a significantly greater
increase in HR (p  0.002) and CO (p  0.00001) in
group I.
A major change in the classification of MS (from the
severe to mild category) occurred in only one patient
assessed by PHT-MVA and in no patient assessed by
2DE-MVA. Classification changed from moderate to mild
in four patients by PHT-MVA and in one patient by
2DE-MVA. Changes in 2DE-MVA did not correlate with
changes in CO (r  0.04) or changes in HR (r  0.008).
Changes in PHT-MVA only correlated weakly with
changes in CO (r  0.247, p  0.05), but had a stronger
correlation with changes in HR (r  0.47, p  0.001).
There was a weak inverse correlation between 2DE-MVA
and PHT-MVA changes and baseline MVA (r   0.30
and r  0.29, respectively; p  0.05). The mitral valve
score showed no correlation with changes in 2DE-MVA
(r  0.07) or changes in PHT-MVA (r  0.13). Intraob-
Table 1. Baseline Characteristics
Age (yrs) 29.4  1.1 (range 14–55)
Gender (F/M) 40/17
NYHA class (n)
Class I 2
Class II 17
Class III 38
Class IV 0
Mitral valve score 6.8  0.2 (range 4–10)
NYHA  New York Heart Association.
Table 2. Hemodynamic Measurements and MVA at Baseline and With Dobutamine Infusion
Baseline Dobutamine Mean Change p Value
HR (beats/min) 80  2 112  3 43.4  4%  0.00001
CO (l/min) 3.8  0.2 5.5  0.2 54.7  4%  0.00001
Stroke distance (cm) 17.5  4.4 18.7  4.2 — NS
Mitral inflow TVI 60.2  3.0 62.8  3.1 — NS
Diastolic filling time (ms) 439  23 327  13 25.4  5% 0.00008
2DE-MVA (cm2) 1.21  0.05 1.35  0.05 10.7  2%  0.00001
PHT-MVA (cm2) 1.20  0.05 1.43  0.06 19.4  3%  0.00001
Data are presented as the mean value  SEM.
2DE  two-dimensional echocardiographic; CO  cardiac output; HR  heart rate; MVA  mitral valve area; PHT  pressure half-time; TVI  time–velocity integral.
Figure 1. Changes in cardiac output during dobutamine administration in
group I (A) and group II (B). *p  0.0001 compared to baseline.
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server variabilities for 2DE-MVA and PHT-MVA were 3
 2% and 5  3%, respectively, whereas interobserver
variabilities were 7  3% and 5  3%, respectively.
DISCUSSION
This study demonstrates that alterations in transmitral flow
are associated with small but clinically insignificant changes
in directly planimetered MVA, as well as somewhat more
pronounced changes in MVA determined by PHT. Classi-
fication of the severity of MS, as defined by MVA, was not
altered in a clinically significant manner in most patients.
The MVA reserve in this patient population with rheumatic
MS without significant calcification was weakly related to
the baseline severity of MS, but not to the flow increase or
mitral valve score. However, changes in PHT-MVA had a
modest correlation with changes in HR. Slightly more than
50% of the patient population had an increase in CO after
dobutamine infusion that was caused predominantly by an
increase in HR; even these patients showed a small increase
in MVA by both methods that was similar to that of
patients whose CO was augmented by an increase in both
HR and stroke volume. This observation suggests that an
increase in stroke volume is not due to an increase in
anatomic MVA in patients with MS.
Earlier invasive hemodynamic studies using the Gorlin
formula to calculate MVA have suggested that MVA in
patients with MS is independent of flow (11,12), and
similar data have been published using the continuity
equation (5,7). However, several studies (5,6,8–10,13) have
suggested that MVA in MS is flow-dependent, and that
this mitral valve “reserve” is dependent on the severity of
pathologic changes, as assessed by the mitral valve score (8).
Thus, whether MVA is flow-dependent or not is still
controversial.
Previous studies of MVA under varying hemodynamic
conditions have been limited by the flow dependence and
HR dependence of the formulae used to estimate MVA.
The MVA determined by the PHT method is rate-
dependent, as shown in this study and previous studies
(5,14). Potential pitfalls associated with the use of the
continuity equation include the difficulty of accurately mea-
suring the LVOT diameter and carefully defining the
Figure 2. (A) Changes in planimetered mitral valve area (MVA) during
dobutamine infusion in group I. (B) Changes in MVA derived by the
pressure half-time method during dobutamine infusion in group I. *p 
0.0001, †p  0.0002 compared with baseline.
Figure 3. (A) Changes in planimetered mitral valve area (MVA) during
dobutamine infusion in group II. (B) Changes in MVA derived by the
pressure half-time method during dobutamine infusion in group II. *p 
0.0035, †p  0.001 compared with baseline.
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LVOT velocity before flow acceleration. The Gorlin for-
mula uses a discharge constant that may be influenced by
hemodynamic conditions and can decrease in low flow
states. Anatomic MVA measured by direct planimetry of
the mitral valve orifice has an excellent correlation with
PHT-MVA, the Gorlin formula, and the continuity equa-
tion at rest (4,5,7). In addition, it has been observed that
2DE-MVA has a strong correlation with direct measure-
ment of the valve orifice at the time of surgery (15).
Evaluation of anatomic MVA under varying hemodynamic
conditions, therefore, is essential to understand the signifi-
cance of flow-related changes in MVA obtained by Doppler
methods. A true widening of the orifice area could occur
with an increase in the opening force, which is related to left
atrial pressure, stroke volume, and transmitral flow rate.
Alternatively, the increase in MVA with augmented flow
could be due to the rate dependence of the formula itself.
Our results demonstrate that there is a small degree of
true widening of the mitral valve orifice in patients with
MS, which is more pronounced in patients with severe
MS at baseline and which does not correlate with an
increase in flow. This suggests that in untreated MS of
varying severity, the mitral valve reserve capacity is finite
and reaches its limit with a small increase in flow, beyond
which MVA remains relatively constant. The flow depen-
dence of MVA measurement is particularly relevant to
the scenario of low CO. These data indicate that the
accuracy of planimetry or PHT methods is not compro-
mised in low output states.
Study limitations. The change in flow obtained in our
patients with MS was statistically significant but limited.
Similar changes in flow with exercise or dobutamine infu-
sion have been reported previously (5–8,11–14,16–18).
Because our patients were relatively young and had rheu-
matic MS without significant valvular calcification, the
results may not be applicable to older patients. In addition,
it is unknown whether patients with significant subvalvular
stenosis would respond similarly. We deliberately excluded
patients who had atrial fibrillation, so as to obtain unifor-
mity in data collection. Patients with atrial fibrillation may
have low CO, low transmitral gradients, and associated left
ventricular dysfunction, and it is unknown whether these
data are applicable to such patients (19).
Clinical implications. Measurement of anatomic MVA by
planimetry provides strong evidence for the presence of a
mitral valve reserve capacity. This reserve capacity is modest
and does not alter the classification of severity of MS in a
clinically meaningful way. Measurement of MVA by
Table 3. MVA at Baseline and During Dobutamine Infusion in Group I Patients
Patient
No.
Age
(yrs)
2DE-MVA
(cm2)
PHT-MVA
(cm2)
CO
(l/min)
HR
(beats/min)
Before During Before During Before During Before During
1 14 0.74 0.79 0.95 0.93 3.06 5.37 118 132
2 35 1.29 1.36 1.31 1.42 3.85 5.81 83 109
3 37 1.60 1.69 1.31 1.44 3.7 5.23 96 116
4 55 1.41 1.57 1.57 1.98 4.23 6.5 82 99
5 29 0.78 1.0 0.69 0.76 3.7 7.1 49 82
6 42 1.29 1.61 1.26 1.63 4.37 8.32 85 129
7 22 0.97 1.13 1.22 1.72 2.71 5.4 89 115
8 37 1.41 1.44 1.42 1.45 4.54 10.07 102 164
9 28 1.97 1.94 2.17 2.68 2.7 4.96 77 100
10 30 2.0 2.35 2.2 2.0 3.27 5.69 91 112
11 27 1.59 1.57 1.56 1.48 3.16 6.16 61 102
12 33 1.86 2.22 2.25 2.6 3.52 5.22 86 126
13 24 1.17 1.25 0.76 0.94 2.74 5.76 50 91
14 30 1.39 1.39 1.18 1.08 3.45 5.74 82 116
15 20 0.84 1.02 0.9 0.86 4.71 7.91 51 67
16 28 1.49 1.68 1.48 1.95 3.5 6.29 76 152
17 23 1.41 1.33 0.81 0.94 2.54 5.8 56 88
18 45 1.55 1.68 1.44 1.86 3.49 5.18 81 130
19 22 1.79 2.09 1.52 2.3 2.69 4.39 71 111
20 25 0.93 1.08 1.05 2.05 1.92 3.57 81 119
21 30 1.68 1.77 1.57 1.98 3.66 6.05 77 146
22 40 0.58 0.71 0.89 1.52 1.57 3.32 51 126
23 27 1.31 1.58 0.92 1.26 6.01 9.08 61 99
24 25 0.92 0.95 0.76 0.79 1.57 2.55 94 117
25 16 1.41 1.35 1.14 N/A 3.93 6.26 70 146
26 30 0.82 1.13 0.93 1.39 3.15 6.26 69 133
27 17 0.98 0.91 1.55 1.3 2.26 4.49 89 139
Mean  SEM 29.3  1.8 1.3  0.075 1.42  0.08 1.29  0.07 1.55  0.11 3.33  0.17 5.863  0.32 77  3 117  4
p value  0.0001 0.0002  0.0001  0.0001
Abbreviations as in Table 2.
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planimetry appears to be reliable in the presence of varying
flow states. Although a small number of patients may
demonstrate flow-related changes in PHT-MVA, the avail-
ability of concomitant planimetric measurement of MVA
can be useful in clarifying the degree of MS. Thus, MVA
measurement by these methods appears to be a reliable tool
to assess the severity of MS under changing hemodynamic
conditions in the majority of patients.
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